Ascletis Pharma Inc., of Hangzhou, China, said ravidasvir is recommended by the World Health Organization's guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus (HCV) infection as a future pan-genotypic direct-acting antiviral agent.